Patients with MSI-H and BRAF-mutated tumours experienced significantly lower PFS (3.1 vs 11.4 months; P=0.008) and OS (14.5 vs 35.5 months; P=0.004) in comparison with those with MSI-H and BRAF wt tumours. The gene discussed is BRAF; the disease is neoplasm.